share_log

Ladenburg Thalmann Maintains Buy on TG Therapeutics, Raises Price Target to $40

Benzinga ·  May 2 09:04

Ladenburg Thalmann analyst Matthew Kaplan maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $39 to $40.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment